A 28-year-old woman presented to her primary care provider with the chief report of persistent itch associated with atopic dermatitis (AD), with itch severity worst on her hands bilaterally. AD was ...

Please provide your email address to receive an email when new articles are posted on . Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients ...

Topline data were announced from two phase 3 trials evaluating amlitelimab for the treatment of moderate to severe atopic dermatitis.

Atopic dermatitis (AD) is a chronic disease that affects an increasing number of children and adults. The skin is dry and ...

What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...

Amlitelimab is effective at improving moderate to severe AD across all body regions, including the difficult-to-treat head and neck region.

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and ...

Amlitelimab, an OX40 ligand–targeting therapy that modulates T-cell-mediated inflammation without causing cell depletion, ...

Please provide your email address to receive an email when new articles are posted on . Food allergy rates included 38.3% with asthma and 20.4% with no asthma. Atopic dermatitis was more severe among ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

On August 1, 2024, L'Institut national d'excellence en santé et services sociaux (INESSS) issued a positive reimbursement recommendation with conditions for Ebglyss as a first-line biological therapy ...